Page 5 - Cancer Drugs

Scientists make progress in cancer research onboard ISS, NASA announces

Nasa scientists, doctors and researchers are involved in the White House's Cancer Moonshot initiative that aims to cut national cancer rates by at least 50 per cent over the next 25 years

Cancer risk from some pesticides comparable to that due to smoking: Study

The effect of exposure to certain pesticides "rivalled" that of smoking in increasing cancer risk in farmers, according to a US study that compiled 69 such chemicals, including four commonly used in India. Researchers found that for three types of cancer -- non-Hodgkin's lymphoma, leukemia and bladder cancer -- the effects of pesticide exposure were "more pronounced" than those of smoking, widely acknowledged as a cancer risk factor. "We present a list of major pesticide contributors for some specific cancers but we highlight strongly that it is the combination of all of them and not just a single one that matters," senior author Isain Zapata, an associate professor at the Rocky Vista University, US, said. The list, compiled in the study published in the journal Frontiers in Cancer Control and Society, features 69 pesticides, including 2,4-D, Acephate, Metolachlor, Methomyl. These four are among many commonly used in India to combat various threats to crop yields, such as insects an

3 cancer drugs now exempt from customs duty; X-ray tubes to become cheaper

The Union minister also brought down the customs duty on X-ray tubes used in medical X-ray machines

Zydus Lifesciences gets Mexican authority nod for cancer remedy biosimilar

Zydus Lifesciences Ltd on Monday said it has received marketing approval from the Mexican regulatory authority for its biosimilar product -- Bhava, used in the treatment of certain types of cancers. Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk), has granted marketing approval for Bhava, a Bevacizumab biosimilar and it will be marketed in different strengths of 100 mg/4 ml and 400 mg/16 ml, Zydus Lifesciences said in a regulatory filing. Bhava is used in the treatment of metastatic colorectal cancer (mCRC), non-squamous non-small cell lung cancer, metastatic breast cancer, glioblastoma, advanced and/or metastatic renal cell carcinoma and ovarian cancer patients, it added. Zydus Managing Director, Sharvil Patel said the approval granted by COFEPRIS is the company's first biosimilars for patients in Latin America. "To bring in greater access and affordability to patients battling critical ailments, we have been developing a pipelin

Delhi fake cancer drugs case: How top hospitals became involved in the scam

Delhi Police chargesheet reveals eight victims, one fatality in fake cancer drug scam. It seized over 140 vials of the fake chemotherapy drug, which had a market value of around Rs 4 crore

AstraZeneca chemotherapy gets US nod for certain type of endometrial cancer

Endometrial cancer ranks as the fourth most prevalent cancer among women in the US. In 2022, it affected more than 66,000 patients

Delaware judge allows more than 70,000 Zantac lawsuits to go forward

In 2019, some manufacturers and pharmacies halted Zantac sales after a chemical called NDMA, which is known to cause cancer, was detected in some pills

AstraZeneca to establish $1.5 billion cancer drug plant in Singapore

The facility, which will be the drugmaker's first end-to-end ADC production site, will be supported by the Singapore Economic Development Board

Zydus Lifesciences inks supply pact with MSN for generic cancer drug in US

Zydus Lifesciences Ltd on Friday announced an exclusive licensing and supply agreement with MSN Laboratories for generic cancer treatment drug Cabozantinib tablets, for the US market. The company's wholly-owned subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with MSN Laboratories for Cabozantinib tablets for the US market, Zydus Lifesciences Ltd said in a regulatory filing. Cabozantinib tablet is the generic version of CABOMETYX of Exelixis. Under the agreement, MSN Laboratories will be in charge of manufacturing and supplying the generic version of CABOMETYX, following the receipt of regulatory approval, the company said. Zydus will exclusively market, distribute, and sell the product in the US market, it added. "MSN was a first sole ANDA (abbreviated new drug application) applicant for Cabozantinib tablets, to submit a substantially complete ANDA with a paragraph IV certification and therefore may be eligible for 180 days o

US FDA approves expanded use of Bristol Myers' cancer cell therapy

The Food and Drug Administration's decision marks the fourth approval for Breyanzi, which can now be used to treat patients who have received two or more prior lines of therapy

Hospital players enhance focus on cancer care amid a surge in cases

By 2025, cancer cases projected to hit 1.57 million, up 13% from 2020

Productivity loss due to oral cancer in India in 2022 at $5.6 bn: Study

A study by the Tata Memorial Centre (TMC), a premier cancer treatment and research institute here, has estimated that the productivity loss of the country due to oral cancer in year 2022 was approximately USD 5.6 billion. India contributes two-thirds of the global mortality due to oral cancer and has a younger population at risk, said the study, which analysed how the disease affected 100 patients treated between 2019 and 2020 with a follow-up of 36 months. The median age of these patients was 47 years at the time diagnosis, and the majority of them were male. The disease-specific survival for early and advanced stages of the disease was 85 per cent and 70 per cent, with a median age of 47 years. "With (a total of) 671 years (referring to these 100 cases) lost prematurely, the loss of productivity was USD 41, 900 for early stage and USD 96, 044 for the advanced stage. Based on population level rates, the total cost of premature mortality was USD 5.6 billion in 2022, representing ..

Many cancer drugs remain unproven 5 yrs after accelerated approval: Study

The U.S. Food and Drug Administration's accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients' lives? In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within five years. Five years after the initial accelerated approval, you should have a definitive answer, said Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research. Thousands of people are getting those drugs. That seems a mistake if we don't know whether they work or not." The program was created in 1992 to speed access to HIV drugs. Today, 85% of accelerated approvals go to cancer drugs. It allows the FDA to grant early approval to drugs that show promising initial results for treating debilitating or fatal diseases. In exchange, drug companies are expected to do rigorous testing and produce

Bandages contain cancer-causing toxic 'forever chemicals', study reveals

A study reveals that bandages contain cancer-causing toxic 'forever chemicals'. The study was performed on 40 different bandages and 18 brands

Prez Murmu launches first homegrown CAR T-cell therapy for cancer patients

Speaking at the launch event, Murmu said indigenous development of the therapy was an example of the Make in India initiative

Now doctors use artificial intelligence for early cancer detection: Experts

Experts say tech still nascent, diversified dataset for correct risk profiling currently unavailable

Rs 100 tablet to prevent resurgence of cancer: All you need to know

This new pill will reduce the side effects of cancer treatment like chemotherapy by about 50 per cent and the chances of getting cancer for a second time by 30 per cent

Russia close to creating cancer vaccine, announces Vladimir Putin

Vladimir Putin did not specify the details of the vaccine but said it could be available to patients soon. According to the WHO, nearly 10 million people die from the disease annually

Biocon gets USFDA approval to market generic anti-cancer medication

Biocon Ltd on Tuesday said it has received approval from the US health regulator for a generic anti-cancer medication. The company has received approval from the US Food and Drug Administration (USFDA) for Dasatinib tablets to market in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, Biocon said in a regulatory filing. The approval will further strengthen the company's portfolio of vertically integrated, complex drug products, it added. Shares of Biocon settled 4.97 per cent higher at Rs 298.75 apiece on the BSE.

India registered 1.41 mn new cancer cases, 910,000 deaths in 2022: WHO

In 2022, India had more than 14.1 lakh new cancer cases and over 9.1 lakh deaths due to the disease, and breast cancer was the most common, according to the latest estimates of the disease's global burden by the World Health Organization (WHO). Cancers of lip, oral cavity and lung were the most common ones in men, accounting for 15.6 and 8.5 per cent of the new cases, respectively, whereas, cancers of breast and cervix uteri were the most frequent ones in women, making up close to 27 and 18 per cent of the new cases, the International Agency for Research on Cancer (IARC), WHO's cancer agency has estimated. It also calculated that the number of people alive within 5 years following a cancer diagnosis was nearly 32.6 lakhs in India. Globally, the agency estimated 2 crore new cancer cases and 97 lakh deaths, and about 5.3 crore people were alive within 5 years following a cancer diagnosis. About 1 in 5 people develop cancer in their lifetime, and roughly 1 in 9 men and 1 in 12 women di